Refine
Year of publication
Document Type
- Doctoral Thesis (64)
Has Fulltext
- yes (64)
Is part of the Bibliography
- no (64)
Keywords
- ABC-Transporter (5)
- MHC Klasse I (2)
- ABC transporter (1)
- ABC-transporter (1)
- ABCE1 (1)
- ATP-Binding Cassette Transporter (ABC) (1)
- ATPase (1)
- Adenosintriphosphatasen (1)
- Antigenprozessierung (1)
- Apoptose (1)
Institute
- Biochemie und Chemie (41)
- Biochemie, Chemie und Pharmazie (17)
- Biowissenschaften (3)
- Georg-Speyer-Haus (2)
- Pharmazie (2)
- Physik (1)
The adaptive immune system protects against daily infections and malignant transformation. In this, the translocation of antigenic peptides by the transporter associated with antigen processing (TAP) into the ER lumen is an essential step in the antigen presentation by MHC I molecules. The heterodimeric ATP-binding cassette transporter (ABC) TAP consist of the two halftransporters TAP1 and TAP2. Each monomer contains an N-terminal transmembrane domain (TMD) and a conserved C-terminal nucleotide-binding domain (NBD). Together, the TMDs build the translocation core and the NBDs bind and hydrolyze ATP, energizing the peptide transport. TAP features an asymmetry in the two ATP-binding sites that are built of several conserved motifs. One motif is the D-loop with the consensus sequence SALD. The highly conserved aspartate of the D-loop of TAP1 reaches into the canonic ATP-binding site and contacts the Walker A motif and the H-loop of the opposite NBD, while the Asp of D-loop of TAP2 is part of the non-canonic ATP-binding site.
To examine this ABC transport complex in mechanistic detail, a purification and reconstitution procedure was established with the function of TAP being preserved. The heterodimeric TAP complex was purified via a His10-tag at TAP1 in a 1:1 ratio of the subunits. Nucleotide binding to the purified transporter was elucidated by tryptophan quenching assays and the affinity constants for MgADP and MgATP were determined to be 1.0 μM and 0.7 μM, respectevely. In addition, the TAP complex shows strict coupling between peptide binding and ATP hydrolysis, revealing no basal ATPase activity in the absence of peptides. Furthermore, TAP was reconstituted into proteoliposomes and the activity was tested by peptide transport and ATP hydrolysis. Interestingly, the kinetic parameters of the transporter in the reconstituted state are comparable to the data gained for TAP in microsomes.
To characterize the functional importance of the D-loop, D-loop mutants of either TAP1 or TAP2 were analyzed. Strikingly, TAP containing a mutated D-loop in TAP1 (D674A) shows an ATP-hydrolysis independent peptide translocation. Accordingly, the MHC I surface expression is similar to the wildtype situation. However, the same mutation in TAP2 (D638A) results in an ATPase dependent peptide transport similar to wildtype, whereas TAP containing mutations in both subunits leads to an inactive transporter. Although all D-loop mutants showed no altered peptide binding activity, the TAP1 mutant is inactive in peptide-stimulated ATPase activity. Strikingly, ATP or ADP binding is strictly required for the peptide translocation. Experiments carried out in proteoliposomes demonstrate that wildtype TAP can export peptides against their gradient when low peptide concentrations are offered. In contrast, the D674A mutant can facilitate peptide translocation along their concentration gradient in the two directions. At high peptide concentrations, TAP is trapped in a transport incompetent state induced by trans-inhibition. In conclusion, a TAP mutant that uncouples solute translocation from ATP hydrolysis was created. Since this passive substrate movement is strictly dependent on binding of ATP or ADP, an active transporter was turned into a “nucleotide-gated facilitator”.
In a cysteine cross-linking approach the conformational changes of TAP during peptide transport and the flexibility of the nucleotide binding domains were examined. Single cysteines were introduced in the D-loops of TAP1 and TAP2. Cross-linking by copper-phenantroline (CuPhe) was possible for all combinations. However, by adding ATP, ADP or peptide to the TAP complex no differences in the cross-linking efficiency were detected. By CuPhe cross-linking TAP was trapped in a conformation, in which the peptide binding site was not accessible. To complete a transport cycle, a flexibility of at least 17.8 Å of the NBDs is needed, since TAP cross-linked by CuPhe (2.0 Å) or bismaleimidoethane (BMOE, 8.0 Å) was transport inactive but when TAP was cross-linked by 1,11-bismaleimido-triethyleneglycol (BM[PEG]3, 17.8 Å) transport activity was preserved.
Der Transport von antigenen Peptiden in das Lumen des endoplasmatischen Retikulums ist ein zentraler Vorgang bei der Antigenprozessierung und ihrer MHC-Klasse-I-vermittelten Präsentation auf der Zelloberfläche. Intrazelluläre Translokation über die ER-Membran erfolgt mit Hilfe von TAP, eines ATP-abhängigen ABC-Transporters. Einer ATP-unabhängigen Substratbindung folgt der eigentliche Transportschritt, dessen Energetisierung einer ATP-Spaltung bedarf. In der vorliegenden Dissertation wurde die ATPase-Aktivität des TAP-Komplexes aufgeklärt und detailliert charakterisiert. Es wurde eine schnelle und schonende Isolierungs- und Rekonstitutionsmethode entwickelt, die es erlaubt, den partiell aufgereinigten TAP-Komplex in Liposomen einzubauen und Funktionsstudien in vitro durchzuführen. Zum ersten Mal war es damit möglich, die Peptid-stimulierte TAP-spezifische ATP-Hydrolyse direkt zu beobachten und deren kinetische Parameter zu bestimmen. Eine direkte Korrelation zwischen Bindungsaffinität des Peptides zu TAP (Bindungskonstante KD) und der halbmaximalen Stimulation der ATPase-Aktivität von TAP (Km,pep) wurde festgestellt. Die Versuche mit den verzweigten Peptiden zeigten, dass Peptide, die nicht transportiert werden können, keine Stimulation der ATPase-Aktivität hervorrufen. Somit wurde die allosterische Interaktion zwischen Peptidbindung, ATP-Hydrolyse und Peptidtransport nachgewiesen. Nach der Entfernung des peptidexportierenden Sec61-Komplexes aus den Proteoliposomen konnte die vorläufige Stöchiometrie des Transportschrittes bestimmt werden. Eine weitere Anwendung fand die Rekonstitutionsmethode bei der Aufklärung des molekularen Wirkungsmechanismus des TAP-Inhibitors US6, indem der TAP-Komplex zusammen mit der aktiven ER-luminalen Domäne von US6 in die Proteoliposomen rekonstituiert wurde. Die Bindung von US6(delta147-183) an die ER-luminalen Bereiche von TAP blockiert die ATP-Bindung an die zytoplasmatischen NBD des Transporters. Die Peptid-induzierte ATP-Hydrolyse wird durch die Inhibition der ATP-Bindung unterbunden, wohingegen die Peptid- und ADP-Bindung von TAP nicht beeinflusst sind.
Innerhalb des adaptiven Immunsystems spielt der Major Histocompatibility Complex (MHC)-Klasse I-Weg der Antigenpräsentation eine essenzielle Rolle bei der Erkennung und Zerstörung Virus-infizierter Zellen. Ein grundlegender Schritt innerhalb dieses Prozesses ist die Translokation endogener Peptide durch den transporter associated with antigen processing (TAP) in das ER-Lumen. Der TAP-Transporter ist zusammen mit verschiedenen Chaperonen und weiteren Faktoren in einem Peptidbeladungskomplex (PLC) assoziiert. Insbesondere Herpesviren, die durch eine lebenslange Persistenz im Wirt und wiederkehrende Reaktivierung unter Stresssituationen gekennzeichnet sind, interferieren direkt mit dem PLC und dem TAP-Transporter. Das varicellovirale Typ-I-Membranprotein UL49.5 inhibiert den TAP-Komplex, wobei das Protein des Rinderherpesvirus (Bovines Herpesvirus 1, BHV-1) zusätzlich die proteasomale Degradation verschiedener Komponenten des PLCs einleitet. Dieser Mechanismus wird durch die C-terminale Domäne des UL49.5-Proteins vermittelt und ist von keinem anderen Virusprotein bekannt. Welche Aminosäuren des Virusproteins jedoch für diese Inhibition und Degradation essenziell sind, wurde bisher nicht aufgeklärt. Ziel der vorliegenden Doktorarbeit war es, die Funktionsweise des BHV-1 UL49.5-Proteins zu verstehen und insbesondere zu analysieren, welche Bereiche des Proteins für die proteasomale Degradation des TAP-Komplexes verantwortlich sind. Das UL49.5-Protein wurde im Rahmen der vorliegenden Arbeit erfolgreich in Insektenzellen und in HeLa-Zellen exprimiert. Mittels Coimmunpräzipitation (Co-IP) wurde daraufhin die Bindung verschiedener UL49.5-Varianten an den TAP-Komplex analysiert. Unterstützt wurden diese Daten durch einen in vivo Interaktionsscreen (BiFC) und in vitro translatiertes UL49.5. Hierbei stellte sich heraus, dass das UL49.5-Protein in Abwesenheit sämtlicher Komponenten des Immunsystems an beide Untereinheiten des TAP-Transporters bindet. Die Bindung erfolgt sowohl an vollständige TAP-Untereinheiten als auch an den sogenannten coreTAP-Komplex, der nur die inneren sechs Transmembranhelices besitzt. Weiterhin wurden systematisch verkürzte UL49.5-Varianten generiert, um wichtige Reste für TAP-Inhibition und proteasomale Degradation zu identifizieren. Interessanterweise sind weder die N-terminale noch die C-terminale Domäne von UL49.5 für die Bindung an den TAP-Komplex zwingend notwendig. Die Bindung an den TAP-Transporter wird demnach über die Transmembrandomäne von UL49.5 vermittelt. Mit Hilfe von Peptidtransport-Analysen wurde die inhibitorische Aktivität verschiedener UL49.5-Mutanten eingehend untersucht. Zusätzlich wurde eine Untersuchung der MHC I-Oberflächenexpression in transient transfizierten HeLa-Zellen etabliert. In diesen Zellen wurde nach Sortierung eine drastisch reduzierte TAP-Konzentration nachgewiesen, die auf proteasomale Degradation des TAP-Komplexes zurückzuführen war. Die Untersuchung von C-terminal verkürzten UL49.5-Mutanten zeigte, dass die letzten zwei C-terminalen Aminosäuren essenziell für die Induktion der TAP-Degradation sind. Die C-terminale Domäne von UL49.5 konnte jedoch, nach Übertragung auf andere Proteine, keine proteasomale Degradation des TAP-Komplexes einleiten. Demnach ist ein weiterer Bereich des Proteins für diesen Prozess zwingend notwendig. Erstaunlicherweise waren auch N-terminal verkürzte UL49.5-Proteine deutlich in ihrer inhibitorischen Funktion beeinträchtigt. Bereits nach der Deletion von 10 N-terminalen Aminosäuren war das Protein nicht mehr in der Lage, eine proteasomale Degradation des TAP-Komplexes einzuleiten. Demnach spielt auch die ER-luminale Domäne von UL49.5 eine wichtige Rolle bei der UL49.5-induzierten TAP-Degradation. Somit wurde ein bisher noch nicht beschriebener neuartiger Inhibitionsmechanismus für das BHV-1 UL49.5-Protein entdeckt. Nach Bindung von UL49.5 über die Transmembrandomäne an beide Untereinheiten des TAP-Transporters scheint die ER-luminale Domäne von UL49.5 ein Signal über die ER-Membran an die zytoplasmatische Domäne zu übertragen, die dann die proteasomale Degradation des TAP-Komplexes einleitet. Es konnte im Rahmen dieser Doktorarbeit erstmals gezeigt werden, dass additive Effekte eines sehr kleinen Virusproteins auf zwei unterschiedlichen Seiten der ER-Membran zu einer proteasomalen Degradation eines sehr großen Membran-Komplexes führen.
Die Transkription vieler Gene wird über den Acetylierungsgrad der Histone reguliert. Entsprechend erweiterte die Entdeckung von Histondeacetylase-Inhibitoren das Verständnis um Transkriptions-Repressoren und ihre Rolle in der Pathogenese beträchtlich. Zur Zeit stehen die Modifikationen der Histondeacetylasen (HDACs) sowie die biologischen Rollen der verschiedenen HDAC-Isoenzyme im Zentrum intensiver Forschungsarbeiten.
In der vorliegenden Arbeit wurde anhand verschiedener Zelllinien und mit murinem Primärmaterial nachgewiesen, dass das gut verträgliche Antiepileptikum Valproinsäure (VPA) ein potenter HDAC-Inhibitor ist. Dies zeigt sich daran, dass VPA in vivo die durch HDACs vermittelte transkriptionelle Repression aufhebt und zur Akkumulation hyperacetylierter Histone führt. In vitro Enzymassays weisen darauf hin, dass VPA selbst und nicht ein hypothetischer Metabolit die Histondeacetylasen hemmt. Darüber hinaus wurde mit Bindungs- und Kompetitionsstudien festgestellt, dass eine Interaktion von VPA mit dem katalytischen Zentrum der HDACs stattfindet.
Weitere Analysen zeigten, dass VPA bevorzugt Klasse I HDACs hemmt. Durch dieses Merkmal einer erhöhten Spezifität bei gleichzeitig guter Bioverfügbarkeit definiert VPA eine neue Klasse von HDAC-Inhibitoren. Hieraus ergeben sich Hinweise auf strukturelle Anforderungen, die ein HDAC-Inhibitor erfüllen muß, um spezifischer und weniger toxisch als konventionelle Chemotherapeutika zu wirken. Außerdem eröffnete das neu entdeckte pharmakologische Wirkungsspektrum von VPA auf HDACs Erkenntnisse um zusätzliche therapeutische Einsatzmöglichkeiten dieses etablierten Arzneimittels. Bereits jetzt wird VPA in klinischen Studien an Patienten mit Krebs verabreicht.
HDAC-Inhibitoren gelten als potentielle Medikamente für die Therapie maligner Neoplasien. Deshalb besteht großes Interesse an den molekularen Mechanismen, mit denen Substanzen dieser Wirkstoffklasse das Wachstum transformierter Zellen in vitro und in vivo hemmen. In den humanen Melanomzelllinien SK-Mel-37 und Mz-Mel-19 bewirken klinisch relevante VPA-Dosen eine zeit- und dosisabhängige Akkumulation von Zellzyklusinhibitoren und hyperacetylierten Histonen, morphologische Veränderungen und eine verringerte Proliferationsrate. Die verminderte Proliferation wird von einem veränderten Zellzyklusprofil und Apoptose unter Beteiligung sowohl der extrinsisch als auch der intrinsisch bedingten Caspase-Kaskade begleitet. Dies manifestiert sich in der Spaltung der Caspasen 3, 8 und 9, einer Schädigung der Mitochondrien, der apoptotischen PARP-Spaltung, einem Abbau der genomischen DNA und einer Inaktivierung des GFP-Proteins.
Diese Analysen in Melanomzellen sprechen dafür, dass die weitgehend selektive Wirkung von VPA auf Klasse I HDACs der Mechanismus ist, mit dem diese Substanz das Wachstum bestimmter Tumorzellen hemmt. Durch Genexpressions-Analysen konnten außerdem neue Modelle zum Einfluss von VPA auf solide Tumoren postuliert werden. Darüber hinaus wurde festgestellt, dass die Expression und Induzierbarkeit der Zellzyklusregulatoren p21WAF/CIP1 und p27Kip1 und des latent cytoplasmatischen Transkriptionsfaktors Stat1 Biomarker für die Sensitivität von Melanomzellen gegenüber HDAC-Inhibitoren sind. Im Einklang hiermit wird die proapoptotische Wirkung von VPA durch das Cytokin Interferon α und den S-Phase-Inhibitor Hydroxyharnstoff deutlich gesteigert. Diese Ergebnisse sprechen für den Einsatz von VPA in tierexperimentellen und klinischen Studien.
Aufgrund der Schlüsselrolle der HDACs für die physiologische und aberrante Genexpression ist es wichtig, die Mechanismen ihrer Regulation zu kennen. In der vorliegenden Arbeit wurde anhand zahlreicher kultivierter Zelllinien und mittels eines Mausmodells gezeigt, dass therapeutisch einsetzbare VPA-Dosen neben der Hemmung enzymatischer Aktivität auch zu einer isoenzymspezifischen Verringerung der Klasse I Histondeacetylase HDAC2 führen. Als Ursache hierfür konnten eine verstärkte Poly-Ubiquitinylierung und ein proteasomaler Abbau ermittelt werden. Gleichzeitig wurden die Beteiligung etlicher Proteasen und eine veränderte Synthese oder Prozessierung der HDAC2-mRNA als Mechanismen ausgeschlossen.
Expressionsanalysen identifizierten die E2 Ubiquitinkonjugase Ubc8 als von HDAC-Inhibitoren induziertes Gen. Mittels transienter Überexpression („Gain-of-Function“) und siRNA-Experimenten („Loss-of-Function“) konnte dieses Gen als limitierender Faktor des HDAC2-Umsatzes in vivo erkannt werden. Weiterhin wurde gezeigt, dass die E3 Ubiquitinligase RLIM spezifisch mit HDAC2 interagiert. Die Expression von RLIM beziehungsweise seine enzymatische Funktion beeinflusst die HDAC2-Konzentration in vivo. Hierbei kann VPA klar von dem HDACInhibitor Trichostatin A (TSA) abgegrenzt werden. Dieser hemmt ein breites Spektrum an HDACs und induziert Ubc8, führt aber gleichzeitig zu einem proteasomal vermittelten Abbau des RLIM-Proteins. Analysen mit überexprimiertem RLIM zeigten, dass TSA aufgrund dieses Mechanismus nicht in der Lage ist, den Abbau von HDAC2 zu induzieren. Somit ist im Rahmen dieser Arbeit die Ubiquitinylierungs-Maschinerie für HDAC2 charakterisiert worden. Hierdurch sind neue Aspekte zum Zusammenspiel zwischen dem Ubiquitin-Proteasom-System und der Transkriptionsrepression nachgewiesen worden.
Isoenzymspezifische HDAC-Inhibitoren können zur Aufklärung der Funktion einzelner Histondeacetylasen beitragen, insbesondere wenn Knock-Out-Studien zu aufwendig oder aufgrund embryonaler Letalität nicht durchführbar sind. Die Wichtigkeit dieser Analysen wird gerade bei HDAC2 deutlich, da diese Histondeacetylase in vielen soliden und hämatologischen Tumoren überexprimiert ist, und ihre Deregulation möglicherweise zur Krebsentstehung beiträgt. Die in der vorliegenden Arbeit identifizierte Regulation dieses HDAC-Isoenzyms könnte Hinweise auf den Ablauf eines malignen Transformationsprozesses geben. Darüber hinaus zeigt der nachgewiesene Regulationsmechanismus Erfordernisse und potentielle Zielstrukturen einer pharmakologischen Intervention auf. Schließlich könnten die Selektivität von VPA für Klasse I HDACs zusammen mit der Spezifität für HDAC2 die Gründe für die geringen Nebenwirkungen der VPA-Behandlung bei gleichzeitigem Auftreten antitumoraler Effekte sein.
Presentation of intracellular processed antigens by major histocompatibility (MHC) class I molecules to CD8+ cytotoxic T lymphocytes is mediated by the macromolecular peptide loading complex (PLC). In particular accessory proteins, including the transporter associated with antigen processing (TAP) and tapasin, play a pivotal role in the MHC class I mediated antigen presentation pathway. TAP belongs to the ATP-binding cassette (ABC) superfamily and consists of TAP1 (ABCB2) and TAP2 (ABCB3), each of which possesses a transmembrane and a nucleotide-binding domain (NBD). The ER-resident glycoprotein tapasin promotes the optimal folding and assembly of MHC-peptide complexes, and independently stabilizes the steady state expression level of TAP. In the present thesis recombinant Fv, scFv and Fab antibody fragments to human TAP from a hybridoma cell line expressing the TAP1-specific monoclonal antibody mAb148.3, were generated. The epitope of the mAb148.3 was mapped to the very last five C-terminal amino acid residues of TAP1 on solid-supported peptide arrays. The recombinant antibody fragments were heterologously expressed in E. coli and insect cells, and purified to homogeneity by affinity chromatography. The monoclonal and recombinant antibodies display nanomolar affinity to the last five C-terminal amino acid residues of TAP1 as demonstrated by enzyme linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). Surprisingly, the recombinant antibody fragments confer thermal stability to the heterodimeric TAP complex in insect cells when incubated at elevated temperature. At the same time, TAP is arrested in a peptide transport incompetent conformation, although ATP and peptide binding to TAP are not affected. Furthermore, the recombinant antibodies were successfully used in the purification of the PLC from a human B-lymphoblastoid cell line and a novel factor, protein disulfide isomerase (PDI), was identified by matrix assisted laser desorption/ionisation-mass spectrometry (MALDI-MS). In the second part of this thesis the tapasin-MHC class I interaction was investigated. It is for this reason, that an in vitro assay had been established for direct measuring tapasin-MHC class I interactions. First, soluble single chain MHC class I molecules were engineered, choosing two MHC class I alleles: HLA-B4402 representing a highly tapasin-dependent allele and with HLA-B4405, a tapasin-independent allele was chosen. Tapasin as well as the two single chain MHC class I constructs, scB4402-b2m and scB4405-b2m, were expressed in insect cells and purified from insect cell supernatants by affinity chromatography. In contrast to the HLA-B4405 allele, which was expressed and secreted at moderate yield, the HLA-B4402 allele was expressed and trapped inside the insect cells instead of secreted into the medium. Peptide-binding and anisotropy measurements with fluorescein-labeled peptides verified the functionality of the scB4405-b2m. For further investigation of the tapasin-MHC class I interaction an in vitro assay was established using surface plasmon resonance spectroscopy. Due to the transient nature of the interaction including the decreased affinity of both interaction partners, kinetic data acquisition was difficult to evaluate. Furthermore, interaction of the scB4405-b2m with the sensor surface itself contributed to the measured interaction. Additionally, to investigate tapasin editing function, tapasin as well as the scB4405-b2m-peptide complex were tethered on fluid chelator lipid bilayers and monitored by reflectance interference (RIf) and total internal reflection fluorescence spectroscopy (TIRFS). Stable immobilization of scB4405-b2m-peptide complex as well as of tapasin was observed, unfortunately no changes in peptide dissociation kinetics monitored in the TIRFS channel were detected. Presumably, the tapasin-independent HLA-B4405 already loaded with a high affinity peptide is not influenced by the peptide-editing function of tapasin. Here, for the first time an in vitro assay was established for direct probing interactions within the various proteins of the PLC.
Two distinct mechanisms contribute to the development of blood vessels: vasculogenesis, which is the de novo formation of vascular structures from progenitor cells, and angiogenesis, the formation of new blood vessels from pre-existing ones.
Angiogenesis is a highly ordered and carefully regulated multi-step process, during which the precise spatio-temporal interaction between endothelial and mural cells, i.e. smooth muscle cells and pericytes, is prerequisite for the formation of a functional blood vessel. The crosstalk between these two latter cell ty pes is mediated indirectly by various
secreted growth factors, and directly through cell-cell and cell-matrix interactions. The secretory epidermal growth factor-like protein 7 (EGFL7) has been implicated to
play an important role in the regulation of smooth muscle and endothelial cell recruitment and vascular tube formation. However, in-depth investigation of the underlying molecular mechanism has so far been hampered by the lack of functional recombinant EGFL7. In this study for the first time full length EGFL7 was successfully expressed as a His 6- tagged fusion protein from insect cells using the Baculovirus expression vector system. Recombinant EGFL7 was purified in a two-step protocol involving ion metal affinity chromatography and gel filtration. Furthermore, recombinant EGFL7 was
purified from human embryonic kidney EBN A 293 cells using a similar approach, allowing the production of high amounts of recombinant EGFL7 protein in its native state, with proper post-translational processing and full biological activity. Detailed analysis of the post-translational processing of recombinant EGFL7 and EGFL7-mutants revealed extensive proteolytic processing by protein convertases both at the N- and the C-terminus, the latter being prerequisite for EGFL7 secretion. Furthermore, secreted EGFL7 protein was shown to bind to the extracellular matrix and the responsible heparin-binding domain of EGFL7 was mapped to its N-terminal
portion. Purified recombinant EGFL7 protein was tested for its functionality using cell migration assays, cell proliferation studies and in vivo matrigel studies in mice. In the
modified Boyden chamber migration assay, recombinant EGFL7 proteins inhibited PDGF-BB-induced smooth muscle cell migration. Moreover, recombinant EGLF7 proteins strongly inhibited PDGF-BB-induced proliferation of smooth muscle cells, while it did not affect VEGF induced proliferation of endothelial cells. When applied in the in vivo matrigel plug assay, EGFL7 proteins induced a strong pro-angiogenic response, comparable with that of VEGF on an equimolar basis. Moreover, EGFL7 expression was strongly induced in endothelial cells in response to VEGF stimulation. These novel findings demonstrate the important function of EGFL7 in angiogenesis and are well in line with previous results. They demonstrate a cell specific action of EGFL7 on the different cell types involved in vessel formation, which is a prerequisite for a regulatory function in cell-to-cell crosstalk. Based on the results described here, the following model can be proposed: VEGF, a known strong initiator of angiogenesis, induces endothelial cell proliferation and migration, allowing the
escape from the comparatively rigid structure of a functional vessel to form an angiogenic sprout. At the same time VEGF induces the expression of EGFL7 in endothelial cells. EGFL7 is expressed, proc essed and secreted from these cells. While EGFL7 has no known effect on endothelial cells, it inhibits smooth muscle cell proliferation and migration, providing a mechanism to prevent pre-mature stabilization of the forming vessel. The availability of purified recombinant EGFL7 will be helpful in the detailed characterization of the underlying molecular mechanism of EGFL7 action, including the identification of the putative EGFL7 receptor, and will allow - together with knock-out experiments in mice - the exploration of the additional biological functions of EGFL7. Moreover, considering the strong pro-angiogenic effect of EGFL7 in vivo, it would be also of a great therapeutic interest to investigate its role in the development of tumor vasculature. The insights into these molecular mechanisms might provide a novel approach for the development of anti tumor therapies.
Biophysical investigation of the ligand-induced assembling of the human type I interferon receptor
(2005)
Type I interferons (IFNs) elicit antiviral, antiproliferative and immunmodulatory responses through binding to a shared receptor consisting of the transmembrane proteins ifnar1 and ifnar2. Differential signaling by different interferons – in particular IFNalpha´s and IFNbeta – suggest different modes of receptor engagement. In this work either single ligand-receptor interactions or the formation of the extracellular part of a signaling complex were investigated referring to thermodynamics, kinetics, stoichiometry and structural organization. Initially an expression and purification strategy for the extracellular domain of ifnar1 (ifnar1-EC) using Sf9 insect cells yielding in mg amounts of glycosylated protein was established. Using reflectometric interference spectroscopy (RIfS) the interactions between IFNalpha2/beta and ifnar1-EC and ifnar2-EC was studied in order to understand the individual energetic contributions within the ternary complex. For IFNalpha2 a Kd of 5 µM for the interaction with ifnar1-EC was determined. Substantially tighter binding of IFNbeta with both ifnar2-EC and ifnar1-EC compared to IFNalpha2 was observed. For neither IFNalpha2 nor IFNbeta stabilization of the complex with ifnar1-EC in presence of soluble ifnar2-EC was detectable. In addition, no direct interaction between ifnar2 and ifnar1 was could be shown. Thus, stem-stem interactions between the extracellular domains of ifnar1 and ifnar2 do not seem to play a role for ternary complex formation. Furthermore, ligand-induced cross-talk between ifnar1-EC and ifnar2-EC being tethered onto solid-supported, fluid lipid bilayers was investigated by RIfS and total internal reflection fluorescence spectroscopy. A very stable binding of IFNalpha2 at high receptor surface concentrations was observed with an apparent kd approximately 200-times lower than for ifnar2-EC alone. This apparent kd was strongly dependent on the surface concentration of the receptor components, suggesting kinetic rather than static stabilization, which was corroborated by competition experiments. These results indicate that signaling is activated by transient cross-talk between ifnar1 and ifnar2, which is by several orders of magnitude more efficiently engaged by IFNbeta than by IFNalpha2. With respect to differential recognition of different IFNs ifnar1-EC was dissected into sub-fragments containing different of the four Ig-like domains. The appropriate folding and glycosylation of these proteins, also purified in mg amounts were confirmed by SDS-PAGE, size exclusion chromatography and CD-spectroscopy. Surprisingly, only one construct containing all three N-terminal Ig-like domains was active in terms of ligand binding, indicating that these domains were required. Competitive binding of IFNalpha2 and IFNbeta to both this fragment and ifnar1-EC was demonstrated. Cellular binding assays with different fragments, however, highlight the key role of the membrane-proximal Ig-like domain for the formation of an in situ IFN-receptor complex and the ensuing signal activation. Even substitution with Ig-like domains from homologous cytokine receptors did not restore high-affinity ligand binding. Receptor assembling analysis on supported lipid bilayer revealed that appropriate orientation of the receptor is required, which is controlled by the membrane-proximal Ig-domain. All results indicate that differential signalling is encoded by the efficiency of signalling complex formation, which is controlled by the binding affinity of IFNs to the extracellular domains of ifnar1 and 2.
LmrA is a member of the ATP Binding Cassette (ABC) transporter family of membrane proteins and a structural and functional homologue of P-glycoprotein1, 2. ABC-transporters share a common architecture of two transmembrane domains and two nucleotide binding domains. The NBDs are highly conserved in this transporter family whereas the TMDs are highly diverse3. The TMDs recognize the substrate and the NBDs bind and hydrolyze ATP and thus contribute the energy for substrate translocation. ABC transporters as a protein family transport a high number of substrates including peptides, nutrients, ions, bile acids, lipids and other lipophilic compounds. LmrA is a multidrug transporter that recognizes a number of hydrophobic substrates including fluorescent dyes and antibiotics1, 4-6. LmrA is a native protein of the gram-positive bacterium Lactococcus lactis. In this thesis, L. lactis was used as a homologous expression host for the preparation of LmrA for a variety of experiments. Wildtype LmrA as well as a number of cysteine mutants were successfully expressed in L. lactis, purified and subsequently characterized by a variety of biochemical assays (Chapter 4). LmrA can be expressed to very high amounts in L. lactis. The purification and reconstitution were optimized for the requirements of solid-state NMR experiments in this thesis. For the first time, an ABC transporter has been reconstituted in synthetic lipids to a ratio of up to 1:150 (mol/mol). LmrA was shown to be active under magic angle spinning conditions with these reconstitution ratios. By taking advantage of the slower ATP hydrolysis by LmrA ΔK388 (lysine deletion in the Walker A motif), a real-time 31P solid-state NMR ATPase assay was established (Chapter 5). This assay allowed, for the first time, the investigation of all phosphor nuclei during the ATP hydrolysis cycle of a membrane protein simultaneously and in real time7. This assay has been successfully adapted to investigate both ATP hydrolysis and substrate phosphorylation of diacylglycerol kinase (together with S. Wollschlag) and ATP hydrolysis at high temperatures of the thermophilic ABC transporter ABC1 from Thermos thermophilus (together with A. Zutz). In the course of this thesis, the gene for LmrA has been cloned into expression vectors suitable for Escherichia coli and the heterologous expression of LmrA was established (Chapter 4). The functionality of the heterologously expressed protein has been investigated and compared to L. lactis LmrA. In these experiments, LmrA was shown to yield a distinct multidrug resistance phenotype in its E. coli host and to show secondary active multidrug transport in the absence of ATP and presence of a proton gradient [Hellmich et al, in prep] (Chapter 4). Previously, it had been shown that LmrA acts as a seconadary active transporter when the NBDs are truncated8. The overexpression in minimal and defined medium and the purification of LmrA from E. coli have been optimized. Isotope labeling for ssNMR has been established and the first multinuclear ssNMR experiments have been carried out on a functional ABC transporter (Chapter 8). ABC transporters couple two cycles: upon ATP binding, the NBDs dimerize, hydrolyze the ATP, subsequently release Pi and ADP and finally dissociate. During this cycle, conformational changes are relayed to the TMDs which utilize the energy from ATP binding and/or hydrolysis to translocate the respective substrate. The prehydrolysis state can be trapped by beryllium fluoride, whereas the post-hydrolysis state of this cycle can be trapped by vanadate9-12. Trapping protocols for these reagents were successfully established for LmrA in this thesis (Chapter 4). This allowed for the investigation of different catalytic states by both ssNMR and EPR. A general 19F labeling protocol for membrane proteins has been established in the course of this thesis and successfully applied to proteorhodopsin (together with N. Pfleger)13 and LmrA (chapter 6). Single cysteine mutants of LmrA that line out the dimer interface have been labeled with a fluorine label for ssNMR. In the apo state, the 19F labeling indicates highly flexible transmembrane domains, a finding that is supported by 13C ssNMR and EPR measurements. The addition of drugs has a different effect on different positions within the LmrA dimer, therefore indicating that different drugs are recognized at a different position within the protein. For P-glycoprotein and LmrA it has been previously shown by biochemical methods that different drug binding sites co-exist. For a 19F label attached at position 314 (LmrA E314C), the spectra showed two distinct peaks with similar populations. This could hint towards a structural asymmetry within the LmrA dimer that might also be reflected in the alternating ATP hydrolysis at the NBDs. E314 has been specifically implicated with drug transport. Thus, structural asymmetry at this position might be functionally relevant for guiding a substrate through the transporter. Structural asymmetry within a homodimeric ABC transporter has also been shown for BtuCD, the E. coli vitamin B12 importer14. In addition, the conserved glutamates in EmrE, a small multidrug resistance protein, were shown to be asymmetric in the drug bound state15. Both, uniformly 13C/15N labeled as well as selectively amino acid type labeled LmrA has been investigated in different conformational states. Interestingly, significant dynamic changes in the b-sheet regions of LmrA (confined to the NBDs) were observed in the pre-hydrolysis (beryllium fluoride) and transition state (vanadate trapped) state. These were interpreted as the transition from a domain in fast conformational exchange in the apo state to one of intermediate exchange in the nucleotide bound state. A significant change in NBD mobility upon nucleotide binding was previously also shown with 2H ssNMR on LmrA16. By EPR it was shown that LmrA in both the vanadate and BeFx trapped states displays a significantly higher rigidity and therefore defined distances, whereas the apo state resembled a “floppy” protein with no preferred distance distribution. This concurs with data obtained from 19F ssNMR with fluorine labeled single-cysteine mutants. Here, in agreement with the EPR data, a higher label (and possibly) protein mobility was observed in the apo state displaying rather broad line widths. Upon trapping with vanadate, the line widths of the majority of fluorine-labeled mutants decreased due to an enhanced protein rigidity and a more homogenous environment of the fluorine labels. A similar observation was made when increasing the temperature that can be explained due to higher protein flexibility at increased temperatures. Solution NMR was employed to investigate the isolated soluble NBD of LmrA (Chapter 9). First 2D and 3D spectra were successfully obtained and could be utilized for a preliminary assignment of a significant fraction of residues. Additionally, binding of ATP and ADP in absence and presence of magnesium was investigated. Finally, the effects of peptides emulating the coupling helices of the full-length transporter on the soluble NBD were investigated. Strikingly, binding of one of these peptides only occurred in the presence of nucleotides (whereas the other showed no binding at all) hinting towards a tightly coupled regulation of the NBD and TMD during the substrate translocation/ATP hydrolysis cycle based on nucleotide binding.
Characterization of mouse NOA1 : subcellular localizaion, G-Quadruplex binding and proteolysis
(2013)
Mitochondria contain their own protein synthesis machinery with mitoribosomes that are similar to prokaryotic ribosomes. The thirteen proteins encoded in the mitochondrial genome are members of the respiratory chain complexes that generate a proton gradient, which is the electromotoric force for ATP synthesis.
NOA1 (Nitric Oxide Associated Protein-1) is a nuclear encoded GTPase that positively influences mitochondrial respiration and ATP production. Although a role in mitoribosome assembly was assigned to NOA1 the underlying molecular mechanism is poorly understood. This work shows that the multi-domain protein NOA1 serves multiple purposes for the function of mitochondria. NOA1 is a dual localized protein that makes a detour through the nucleus before mitochondrial import. The nuclear shuttling is mediated by a nuclear localization signal and the now identified nuclear export signal. SELEX (Systemic Evolution of Ligands by Exponential Enrichment) analysis revealed a G-quadruplex binding motif that characterizes NOA1 as ribonucleoprotein (RNP). G-quadruplex binding was coupled to the GTPase activity and increased the GTP hydrolysis rate. The sequence of localization events and the identification of NOA1 being a RNP lead to the discussion of an alternative import pathway for RNPs into mitochondria. The short-lived NOA1 contains ClpX recognition motifs and is specifically degraded by the mitochondrial matrix protease ClpXP. NOA1 is the first reported substrate of ClpXP in higher eukaryotes and augments the contribution of the ClpXP protease for mitochondrial metabolism. To assess the direct action of NOA1 on the mitoribosome co-sedimentation assays were performed. They showed that the interaction of NOA1 and the mitoribosome is dependent on the GTPase function and the nascent peptide chain. In vitro, NOA1 facilitated the membrane insertion of newly translated and isotope labeled mitochondrial translation products into inverted mitochondrial inner membrane vesicles. In conclusion, NOA1 is a G-quadruplex-RNP that acts as mitochondrial membrane insertion factor for mtDNA-encoded proteins.
This thesis provides a comprehensive model of the molecular function of NOA1 and is the basis for future research. The identification of NOA1 as ClpXP substrate is a major contribution to the field of mitochondrial research.
Paramyxo- and pneumoviruses include many pathogens with great relevance for human and animal health. To identify common host factors involved in the Paramyxo- and Pneumoviridae life cycle as a basis for new insights in the biology of these viruses and the development of rationally designed therapeutics, genome scale siRNA screens with wild-type measles, mumps, and respiratory syncytial viruses in A549 cells, a human lung adenocarcinoma cell line, were performed. A comparative bioinformatics analysis yielded different members of the coatomer complex I, the translation factors ABCE1 and eIF3A, and several RNA binding proteins as cellular proteins with proviral activity for all three viruses. The strongest common hit, ABCE1, an ATP-binding cassette transporter member, was chosen for further study. We found that ABCE1 supports replication of all three viruses, confirming its importance for both virus families. While viral protein kinetics showed that ABCE1 knockdown resulted in a drastic decrease of MeV protein expression, viral mRNA kinetics are not directly affected by a reduction of ABCE1.
The impact of ABCE1 on viral and global cellular translation was investigated using both 35S metabolic labelling and non radioactive fluorescent protein labelling. ABCE1 knockdown strongly inhibited the production of MeV proteins, while only modestly affecting global cellular protein synthesis and showed that ABCE1 is specifically required for efficient viral, but not general cellular, protein synthesis, indicating that paramyxoand pneumoviral mRNAs may exploit specific translation mechanisms.
In a second approach the efficacy of the small-molecule polymerase inhibitor ERDRP-0519 against MeV was assessed in squirrel monkeys. Animals treated with the drug experienced less severe clinical disease compared to untreated controls, and this effect correlated with the onset of drug treatment.
We observed a reduction of levels of PBMC-associated viremia and virus release in the upper airways, illustrating effective inhibition of virus replication by the drug treatment. ERDRP-0519 drug treatment also alleviated MeV-induced immunosuppression. In addition to providing proof-of-concept for the support of MeV eradication efforts by preventing disease and transmission with a small-molecule polymerase inhibitor, this dissertation provides a novel perspective on cellular proteins that impact the replication of MeV, MuV and HRSV and highlights the role of ABCE1 as host factor that is required for efficient paramyxo- and pneumovirus translation.